Sotagliflozin
- Generic Name
- Sotagliflozin
- Brand Names
- Inpefa
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClO5S
- CAS Number
- 1018899-04-1
- Unique Ingredient Identifier
- 6B4ZBS263Y
- Background
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m. Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as canagliflozin and dapagliflozin, b...
- Indication
用于体重指数≥27kg/m2且接受最佳胰岛素疗法仍无法达到足够血糖控制的1型糖尿病（T1D）成人患者。
- Associated Conditions
- Cardiovascular Mortality, Heart Failure
- Associated Therapies
- -
Antithrombotic Activities of Sotagliflozin vs. Empagliflozin
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 16
- Registration Number
- NCT06618976
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Diagnostic Utility of SGLT1/2 Inhibition to Facilitate Myocardial Glucose Suppression
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 40
- Registration Number
- NCT06510894
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Lexicon Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT06481891
- Locations
- 🇺🇸
Lexicon Investigation Site (4037), Scottsdale, Arizona, United States
🇺🇸Lexicon Investigation Site (4035), Pomona, California, United States
🇺🇸Lexicon Investigational Site (4024), Tulsa, Oklahoma, United States
Sotagliflozin in Patients with Heart Failure Symptoms and Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- University of Dundee
- Target Recruit Count
- 320
- Registration Number
- NCT06435156
Sodium Glucose Co-transporter (SGLT) Inhibitors in Nonobstructive Hypertrophic Cardiomyopathy
- Conditions
- Interventions
- First Posted Date
- 2024-05-29
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 26
- Registration Number
- NCT06433050
Sotagliflozin to Slow Kidney Function Decline in Persons with Type 1 Diabetes and Diabetic Kidney Disease
- Conditions
- Interventions
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Alessandro Doria
- Target Recruit Count
- 150
- Registration Number
- NCT06217302
- Locations
- 🇺🇸
Barbara Davis Center / University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Joslin Diabetes Center, Boston, Massachusetts, United States
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
- Conditions
- Interventions
- First Posted Date
- 2023-11-27
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 69
- Registration Number
- NCT06147232
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Steno Diabetes Center Copenhagen
- Target Recruit Count
- 2000
- Registration Number
- NCT06082063
Ambrisentan Sotagliflozin and Prevention of Renal Injury; a Randomized Evaluation
- Conditions
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2023-10-24
- Lead Sponsor
- University Medical Center Groningen
- Target Recruit Count
- 36
- Registration Number
- NCT06072326
- Locations
- 🇨🇦
University of Toronto, Toronto, Canada
🇫🇮University of Helsinki, Helsinki, Uusimaa, Finland
🇳🇱Amsterdam University Academic Center, Amsterdam, Noord Holland, Netherlands
Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 24
- Registration Number
- NCT05696366
- Locations
- 🇺🇸
UC San Diego Altman Clinical & Translational Research Institute, La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.